Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data

Autor: Antoine Pitoy, Solène Desmée, François Riglet, Hoai‐Thu Thai, Zandra Klippel, Dorothée Semiond, Christine Veyrat‐Follet, Julie Bertrand

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 12, Pp 2087-2101 (2024)

Abstract This study aimed at leveraging data from phase I/II clinical trials to build a nonlinear joint model of serum M‐protein kinetics and progression‐free survival (PFS) accounting for the effects of isatuximab (Isa), pomalidomide (Pom), and

Externí odkaz: https://doaj.org/article/3512273683014dadb38eb1330f450b50

Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study

Autor: Hugues Michelon, Céline Verstuyft, François Riglet, Aurélie Barrail-Tran, Caroline Barau, Henri Benech, Antoine Durrbach, Valérie Furlan, Julie Bertrand

Publikováno v: Drugs in R&D
Drugs in R&D, 2020, 20 (4), pp.331-342. ⟨10.1007/s40268-020-00319-y⟩
Drugs in R&D, Springer Verlag, 2020, 20 (4), pp.331-342. ⟨10.1007/s40268-020-00319-y⟩
Drugs in R&D, Vol 20, Iss 4, Pp 331-342 (2020)

Background and Objective Mycophenolate mofetil is widely used in kidney transplant recipients. Mycophenolate mofetil is hydrolysed by blood esterases to mycophenolic acid (MPA), the active drug. Although MPA therapeutic drug monitoring has been recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9dafe18b12d7b5a915e582173255371
https://hal.inrae.fr/hal-03209277/document